Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OBIO
Strong SellHot AirOrchestra BioMed Holdings, Inc. · Healthcare · United States · $312M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Orchestra BioMed Holdings, Inc. is a medical device company focused on developing disruptive therapies for heart failure and hypertension, with its lead product, BackBeat Cardiac Neuromodulation Therapy (CNT), targeting improved outcomes for HFpEF patients. Its competitive moat lies in its proprietary, patented technology addressing significant unmet medical needs in large patient populations, potentially establishing a new standard of care. Orchestra BioMed is a clinical-stage company leveraging strategic partnerships with major medical device firms to validate and commercialize its innovative solutions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.5M | 2.8M | 2.6M | 33.5M | 111.6% | 32.0M | 0.4M | 0.6M | -86.9% |
| EPS | -1.06 | -1.48 | -1.66 | -1.11 | — | -0.84 | -1.52 | -1.52 | — |
| Shares | 31.6M | 35.8M | 38.2M | 57.0M | +80.4% | 60.1M | — | — | — |
| Debt | 11.9M | 1.7M | 16.5M | 16.0M | 10.4% | 70.8M | — | — | — |
| Equity | 52.5M | 68.0M | 33.0M | 53.6M | 0.7% | — | — | — | — |
| Op CF | -29.3M | -46.1M | -50.6M | -49.0M | — | -58.3M | — | — | — |
| Inv CF | -64.1M | 10.7M | 13.1M | -26.9M | — | — | — | — | — |
| Fin CF | 103.3M | 46.2M | 29.2M | 88.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OBIO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OBIO | Orchestra BioMed Holdings, Inc.(you) | $312M | 19 | Strong Sell |
| IMRX | Immuneering Corporation | $323M | 19 | Strong Sell |
| VNDA | Vanda Pharmaceuticals Inc. | $320M | 18 | Strong Sell |
| FATE | Fate Therapeutics, Inc. | $291M | 21 | Sell |
| FULC | Fulcrum Therapeutics, Inc. | $294M | 17 | Strong Sell |
| IRD | Opus Genetics, Inc. | $307M | 22 | Sell |
| ALXO | ALX Oncology Holdings Inc. | $277M | 17 | Strong Sell |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $360M | 17 | Strong Sell |
| IPSC | Century Therapeutics, Inc. | $367M | 17 | Strong Sell |
| DMAC | DiaMedica Therapeutics Inc. | $345M | 16 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%